Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Locus Biosciences Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 distinct examiners and 3 distinct art units, with at least one art unit receiving matters from more than one examination assignment.
BLUMEL, BENJAMIN P is the busiest examiner, with 1 pending matter. Portfolio management should combine examiner-specific responses with coordinated technical support for the biotechnology and pharmaceutical subject matter.
The distribution across three art units makes classification-level consistency useful, but the separate examiner assignments mean that arguments and amendments should remain tied to each matter’s record.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
| VYAS, KEYUR ANILKUMAR | 1 | 50.0% | +58.7% |
| BATES, KEENAN ALEXANDER | 1 | 44.9% | +79.8% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 47.2% | +63.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18862452 | PHAGE COMPOSITIONS FOR ESCHERICHIA COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | BLUMEL, BENJAMIN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17774393 | PHAGE COMPOSITIONS COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | LIPPOLIS, ALEXANDRA ROSE | 15d |
| 18862452 | PHAGE COMPOSITIONS FOR ESCHERICHIA COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | BLUMEL, BENJAMIN P | — |
| 18035227 | PHAGE COMPOSITIONS FOR PSEUDOMONAS COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | VYAS, KEYUR ANILKUMAR | — |
| 18033988 | PHAGE COMPOSITIONS FOR ESCHERICHIA COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | BATES, KEENAN ALEXANDER | — |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| 1653 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18862452 | PHAGE COMPOSITIONS FOR ESCHERICHIA COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | BLUMEL, BENJAMIN P | 1653 | §102§103§112 | Non-Final OA | — | Pending | Nov 01, 2024 |
| 18035227 | PHAGE COMPOSITIONS FOR PSEUDOMONAS COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | VYAS, KEYUR ANILKUMAR | 1637 | §112 | Non-Final OA | — | Pending | May 08, 2023 |
| 18033988 | PHAGE COMPOSITIONS FOR ESCHERICHIA COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | BATES, KEENAN ALEXANDER | 1631 | §112 | Final Rejection | — | Pending | Apr 26, 2023 |
| 17774393 | PHAGE COMPOSITIONS COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103 | Non-Final OA | 15d | Pending | May 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLocus Biosciences Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Benjamin P Blumel has the most, with 1 of Locus Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
